Sodium fondaparinux

Mechanism of action

Fondaparinux sodium exerts its pronounced antithrombotic effect through interaction with the natural coagulation inhibitor — antithrombin III. By binding to it, the drug specifically alters the conformation of the active center of antithrombin. This leads to a dramatic acceleration of factor Xa inactivation (to a significantly greater extent than low-molecular-weight heparins do).

The most critical structural feature of the molecule is its length, comprising exactly 5 saccharide units. Due to such a short chain, the drug is physically incapable of simultaneously binding to antithrombin III and thrombin (factor IIa) — this requires a longer molecule, like that of standard heparin. As a result, fondaparinux possesses absolute selectivity and does not inhibit thrombin.

Pharmacokinetics and safety profile

The pharmacokinetic profile of the drug compares favorably with its predecessors due to high predictability. Fondaparinux sodium does not bind to plasma proteins, cellular elements, or the vascular endothelium at all.

• Absorption: Upon subcutaneous administration, the drug is completely absorbed, and its bioavailability reaches an absolute 100% (for comparison, standard heparin has a bioavailability of only 20–30%).
• Duration of action: The half-life ($T_{1/2}$) is very long, at approximately 17 hours. This ensures a stable effect and minimizes the frequency of injections.
• Effect on platelets: The drug does not affect platelet aggregation, which makes the risk of bleeding lower than when using unfractionated heparin. Furthermore, it binds only minimally to platelet factor 4. Due to this, the risk of developing severe immune heparin-induced thrombocytopenia (HIT) is extremely low (less than 1%).
• Bone tissue: Unlike standard heparin, fondaparinux therapy does not lead to the development of osteoporosis.

Evolution of anticoagulants

The development of drugs activating antithrombin III progressed toward increased selectivity and safety. With the transition from unfractionated heparin to low-molecular-weight heparins (LMWHs) and, finally, to fondaparinux, a logical decrease in molecular weight (from ~15,000 Da to 1,500 Da) and shortening of the chain length (from 40 to 5 units) is observed.

This structural simplification cardinally changes the mechanism of action. While standard heparin is non-selective and inhibits factors Xa and IIa in a 1:1 ratio, and LMWHs act predominantly on factor Xa (2–4:1 ratio), fondaparinux becomes a highly selective inhibitor exclusively of factor Xa. In parallel with the reduction of the molecule, bioavailability increases and the half-life is prolonged, making therapy more manageable.

Clinical application

The drug is available as a sodium salt and is intended for subcutaneous administration. The main clinical advantage stemming from its stable pharmacokinetics is the absence of the need for constant laboratory monitoring of blood coagulation parameters. This fundamentally distinguishes it from standard heparin, which requires strict control in a hospital setting, and allows fondaparinux to be safely used in outpatient treatment.

The main indications for prescription include:

1. Acute myocardial infarction.
2. Unstable angina.
3. Prevention of venous thrombosis and pulmonary embolism (PE), which is particularly sought-after in surgical practice during orthopedic surgeries.

It is important to remember the issue of the antidote: fondaparinux does not bind to protamine sulfate, so no specific drug exists to rapidly neutralize its effect.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Pathogenesis of heparin-induced thrombocytopenia and the role of platelet factor 4.
• Comparative pharmacokinetics of unfractionated heparin and low-molecular-weight heparins (LMWHs).
• Mechanism of osteoporosis development during long-term therapy with standard heparin.
• Features of anticoagulant use for the prevention of PE in orthopedic surgery.
• The role of antithrombin III in the natural hemostasis system.

Other topics in the section "Drugs affecting hemostasis and thrombosis"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.